Small molecule · developed by Sunshine Lake Pharma Co.
HEC89736 is an orally administered tablet taken once daily in 28-day cycles. It is studied in relapsed or refractory B-cell hematologic malignancies.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04865458 | Phase 1 | Relapsed or Refractory B-cell Hematologic Malignancies | Terminated | SBFM |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Relapsed or Refractory B-cell Hematologic Malignancies
Updated Nov 1, 2026. Something wrong or missing? Report it on the SBFM page.
See SBFM's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
SBFM catalysts and pipeline →